Overall survival (OS) in patients (pts) with advanced breast cancer (ABC) with visceral metastases (mets), including those with liver mets, treated with ribociclib (RIB) plus endocrine therapy (ET) in the MONALEESA (ML) -3 and -7 trials.

Denise A. Yardley,Arnd Nusch,Yoon Sim Yap,Gabe S. Sonke,Thomas Bachelot,Arlene Chan,Patrick Neven,Dennis J. Slamon,Paul Wheatley-Price,Agnes Lteif,Manu Sondhi,Karen Rodriguez-Lorenc,A Gaur,Stephen Chia

Overall survival (OS) in patients (pts) with advanced breast cancer (ABC) with visceral metastases (mets), including those with liver mets, treated with ribociclib (RIB) plus endocrine therapy (ET) in the MONALEESA (ML) -3 and -7 trials.

2020

Denise A. Yardley
Arnd Nusch
Yoon Sim Yap
Gabe S. Sonke
Thomas Bachelot
Arlene Chan
Patrick Neven
Dennis J. Slamon
Paul Wheatley-Price
Agnes Lteif
Manu Sondhi
Karen Rodriguez-Lorenc
A Gaur
Stephen Chia

1054Background: In the Phase III ML-3 (NCT02422615) and ML-7 (NCT02278120) trials, RIB + ET demonstrated a significant OS benefit (ML-3: HR, 0.72, P = 0.00455; ML-7: HR, 0.71, P = 0.00973) over pla...

Keywords:

Cancer
Oncology
advanced breast
endocrine therapy
overall survival
Internal medicine
in patient
Pathology
Medicine
Ribociclib

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations